HEALTH OF WOMAN. 2016.9(115):33–39; doi 10.15574/HW.2016.115.33 
 

Analysis of the results of the nationwide study of drug Laferomax in complex therapy of urogenital infections and cervical pathology in women of different age

Borys E. N., Gervazuk O. I.

Ukrainian state Institute of Reproductology, National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The article presents the results of a multicentre observational study conducted in Ukraine in 2015-2016. The purpose of which was to investigate the efficacy and safety of Laferomaks drug in women of different ages with HPV infection, combined with urogenital disorders mixed infection and cervical epithelium pathology. In 128 hospitals obstetrical and gynecological almost all regions of Ukraine was carried out a multicentre observational study, which was attended by 1 400 patients with various diseases of the pelvic organs. Studied Age ranged from 17 to 95 years. All included in the study was conducted a comprehensive survey, after which all patients received Laferomaks 3 million units. per day for 10 days in a combination or alone. Results of the study confirm the high efficiency of Laferomaks in the treatment of the urogenital tract infections: in patients with a diagnosis of CIN 1 and CIN 2 at follow-up examination CIN 0 probability was about 76%; in patients with warts was noted in 83% of their complete disappearance; in patients with a diagnosis of HPV in 71% indicated a negative result of PCR after treatment. It registered only 58 cases of side effects from the 1400, which made up 4.1%, which ensured to Laferomaks high compliance of patients. Received positive dynamics of subjective and objective state of the women surveyed, marked by high efficiency, good tolerability and safety of the drug Laferomaks.

Key words: human papillomavirus, cervical pathology, urogenital mixed infection, Laferomaks.

REFERENCES

1. Anoshina TM. 2005. Optimizatsiya podhodov k prognozirovaniyu, diagnostike i lecheniyu fonovyih i predrakovyih zabolevaniy sheyki matki. Diss.kand. med. nauk. K:294.

2. Batyirshina SV. 2010. Urogenitalnyiy hlamidioz: antibakterialnaya terapiya i sposobyi potentsirovaniya ee effektivnosti. Prakticheskaya meditsina 43:57–61.

3. Bebneva TN, Prilepskaya VN. 2001. Papillomavirusnaya infektsiya i patologiya sheyki matki. Ginekologiya 3;3:77–81.

4. Bohman YaV. 2002. Rukovodstvo po onkoginekologii. SPb, «OOO Izdatelstvo Foliant»:542.

5. Vakulenko GA, Schepotin IP, Kohanevich EV. 2004. Predopuholevyie zabolevaniya sheyki matki. Iskusstvo lecheniya 12:10–117.

6. Vorobeva LI, Ligirda NF. 2009. Rol protivovirusnoy terapii v kompleksnom lechenii tservikalnoy intraepitelialnoy neoplazii legkoy stepeni. Zdorove zhenschinyi 7(43):125–128.

7. Zabolevaniya sheyki matki, vlagalischa i vulvy (klinicheskie lektsii). Pod red. VN Prilepskoy. 2-e izd. M, MEDpress. 2000:432.

8. Kartashov SM, Beloded OA. 2009. Analiz effektivnosti deystviya immunomodulyatorov, ispolzuemyih v lechenii papillomavirusnoy infektsii. Zdorove zhenschiny 7(43):161–164.

9. Kozlova VI, Puhner AF. 1997. Virusnyie, hlamidiynyie i mikoplazmennyie zabolevaniya genitaliy: Rukovodstvo dlya vracha. M, IID «Filin»:536.

10. Kohanevich EV, Ganina KP, Sumenko VV. 2004. Kolpotservikoskopiya. Atlas. K, Gidromaks:116.

11. Kulakov VI, Apolihina IA, Prilepskaya VN dr. 2000. Sovremennyie podhodyi k diagnostike papillomavirusnoy infektsii genitaliy u zhenschin i ih znachenie dlya skrininga raka sheyki matki (obzor literaturyi). Ginekologiya 1;2:4–8.

12. Kustarov VN, Linde VA. 2002. Patologiya sheyki matki. SPb, Gippokrat:144.

13. Lakatosh VP. 2001. Sovremennyie podhody k diagnostike, lecheniyu i prognozirovaniyu zabolevaniy sheyki matki, assotsiirovannyih s papillomavirusnoy infektsiey. Diss. d-ra med. nauk. K:297.

14. Levonchuk EA, Yahnitskiy GG. 2013. Papillomavirusnaya infektsiya: lechenie i profilaktika. Mezhdunarodnyie obzoryi: klinicheskaya praktika i zdorove 2:49–53.

15. Ligirda NF. 2006. Obosnovanie kompleksnogo organosohranyayuschego lecheniya tservikalnyih intraepitelialnyih displaziy i nachalnogo raka sheyki matki u patsientok molodogo vozrasta. Diss. kand. med. nauk. K:298.

16. Melehova NYu. 2005. Papillomavirusnyie porazheniya sheyki matki u patsientok razlichnogo vozrasta. Diss. d-ra med. nauk. M:297.

17. Rogovskaya SI, Prilepskaya VN. 2008. Novyie tehnologii v profilaktike raka sheyki matki. Ginekologiya 10;1:4–7.

18. Prilepskaya VN. 2005. Zabolevaniya sheyki matki, vlagalischa i vulvi. M, «MEDpress-inform»:430.

19. Peterson EE. 2007. Infektsii v akusherstve i ginekologii. Eyko E. Peterson: Per. s angl. M, MEDpress-inform:352.

20. Tazulahova EB. 1996. Induktsiya i produktsiya interferonov. V sb.: Sistema interferona v norme i pri patologii. M, «Meditsina»:71–87.

21. Voloshina NN. 2007. Tservikalnyie intraepitelialnyie neoplazii (diagnostika, lechenie i profilaktika): Metodicheskie rekomendatsii. Zaporozhe:36.

22. Shperling NV. 2009. Terapevticheskaya effektivnost i osobennosti deystviya preparatov interferona i induktorov interferona pri variantah techeniya virusnyih urogenitalnyih infektsiy. Diss. d-ra med. nauk. Tomsk.

23. Bosch FX, Lorincz A, Munoz N et al. 2002. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 55:244–65. https://doi.org/10.1136/jcp.55.4.244; PMid:11919208 PMCid:PMC1769629

24. Vinokurova S, Wentzensen N, Einenkel J et al. 2005. Clonal history of papillomavirus-induced displasia in the female lower genital tract. J. Natl. Cancer. Inst. 97;24:1816–1821. https://doi.org/10.1093/jnci/dji428; PMid:16368943

25. de Jong A, van Poelgeest MI, van der Hulst JM et al. 2004. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64:5449–55. https://doi.org/10.1158/0008-5472.CAN-04-0831; PMid:15289354

26. Hamada K, Shirakawa T, Gotoh A, Roth JA, Follen M. 2006. Adenovirus mediated transfer of human papillomavirus 16 E6/E7 antisese RNA and induction of apoptosis in cervical cancer. Gynecol. Oncol. 12.

27. Schlecht NF, Kulaga S, Robitaille J et al. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106–14. https://doi.org/10.1001/jama.286.24.3106; PMid:11754676

28. Sedlacek TV. 1999, Jun. Advances in the diagnosis and treatment of human papillomavirus infection. Clin Obstet Gynnecol. 42(2):206–220. https://doi.org/10.1097/00003081-199906000-00006; PMid:10370842

29. Uuskula A, Kohl PK. 2002. Genital mycoplasmas, including Mycoplasma genitalium, as sexually transmitted agents. Int J STD AIDS. 13(2):79–85. https://doi.org/10.1258/0956462021924695; PMid:11839161